Fresolimumab ([255] (Sanofi, GC1008) is a high affinity fully human monoclonal antibody that is a pan neutralizing antibody for all three TGFβ isoforms with promising clinical findings in non-ovarian cancers and particularly breast cancer patients receiving radiotherapy [255, 256]. The gene discussed is TGFB1; the disease is ovarian cancer.